NILCO biomarkers in breast cancer from Chinese patients

BMC Cancer

Table 2 Cellular localization of NILCO and targets within TNBC, ER+ and ER- breast cancer tissues

Antigen	ER- (n=21)	ER+ (n=33)	TNBC (n=13)	P-value*
Notch1	% positive	% positive	% positive
Nucleus	90	97	83	0.0661
Cytoplasm	90	97	92	0.2480
Stroma	100	100	67	<.001
Notch4
Nucleus	74	74	42	0.0151
Cytoplasm	90	77	50	0.0762
Stroma	100	100	67	<.001
JAG1
Nucleus	84	77	50	0.0281
Cytoplasm	90	88	75	0.0694
Stroma	100	100	100	-
DLL4
Nucleus	90	88	100	0.098
Cytoplasm	90	88	100	0.098
Stroma	0	0	0	-
Leptin
Cytoplasm	68	65	100	<.001
Stroma	68	59	67	0.4055
OB-R
Cytoplasm	84	71	67	0.3023
Stroma	84	79	83	0.3311
IL-1R tI
Cytoplasm	90	97	83	0.3867
Stroma	100	100	83	0.2736
VEGF
Nucleus	58	94	92	0.4221
Cytoplasm	100	91	92	0.4414
Stroma	91	100	100	-
VEGFR2
Nucleus	84	85	50	0.0901
Cytoplasm	90	85	75	0.2668
Stroma	32	35	100	<.001

Staining for NILCO and targets within cancer (nucleus and cytoplasm) and tumor stroma is expressed as % of positive immunoreactivy in each group of breast cancer. ER: estrogen receptor; TNBC: triple negative breast cancer; Notch1 and 4: Notch receptor type 1 and 4; JAG1: Jagged1, a Notch ligand; DLL4: Delta like ligand 4, a Notch ligand; OB-R: leptin receptor; IL-1RtI: interleukin 1 receptor type I; VEGF: vascular endothelial growth factor; VEGFR2: vascular endothelial growth factor 2. *The p-value is calculated by ANOVA. Numbers in ”bold” show significant differences.

ISSN: 1471-2407